Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Primary Myelofibrosis 1Myelodysplastic-Myeloproliferative Diseases 1Immune Checkpoint Inhibitors (ICI)-Related Dermatitis 1COVID-19 1

Interventions

Standard of Care 8Surveys and Questionnaires 7COVID-19 Vaccines 6Blood Specimen Collection 6BNT162 Vaccine 6Specimen Handling 52019-nCoV Vaccine mRNA-1273 5Hydroxychloroquine 4Surgical Procedures, Operative 3Practice Guidelines as Topic 3tocilizumab 2sotrovimab 2sinovac COVID-19 vaccine 2cilgavimab and tixagevimab drug combination 2Sodium Chloride 2Pandemic Preparedness 2Data Collection 2CVnCoV COVID-19 vaccine 2COH04S1 COVID-19 vaccine 2Azithromycin 2selinexor 1remdesivir 1regorafenib 1proxalutamide 1palbociclib 1ogalvibart 1monalizumab 1lenzilumab 1heterologous prime boost COVID-19 vaccination 1crexavibart 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
COVID-19 × Janus Kinase Inhibitors × Clear all
NCT04404361 2024-06-05

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

CTI BioPharma

Phase 2 Terminated
200 enrolled 16 charts

COVID-19

Data powered by HemOnc (CC BY 4.0) Colophon âš¡